INTRODUCTION The success of autologous stem cell transplantation (ASCT) for treating non-Hodgkin's lymphoma (NHL) is limited by its high relapse rates. To reduce the risk of relapse, additional maintenance therapy can be added post-transplant. In a non-transplant setting at the time of initiation of this study, both bortezomib and vorinostat had been studied alone or in combination for some NHL histology and showed some clinical activity. At our center, this combination therapy post-transplant for Multiple Myeloma (MM) showed acceptable toxicity. Therefore, it seemed reasonable to study this combination therapy post-ASCT for NHL. METHODS NHL patients underwent conditioning for ASCT with rituximab, carmustine, etoposide, cytarabine, melphalan (R-BEAM)/carmustine, etoposide, cytarabine, melphalan (BEAM). After recovery from the acute transplant-related toxicity, combination therapy with IV bortezomib and oral vorinostat (BV) was started and was given for a total of 12 (28-day) cycles. RESULTS Nineteen patients received BV post ASCT. The most common toxicities were hematologic, gastrointestinal, metabolic, fatigue and peripheral neuropathy. With a median follow-up of 10.3 years, 11 patients (58%) are alive without disease progression and 12 patients (63%) are alive. CONCLUSIONS BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.

中文翻译：

---

使用 R-BEAM 或 BEAM 移植调理方案，硼替佐米和伏立诺他疗法作为非霍奇金淋巴瘤自体移植后的维持治疗。

引言 自体干细胞移植（ASCT）治疗非霍奇金淋巴瘤（NHL）的成功受到其高复发率的限制。为了降低复发风险，可以在移植后添加额外的维持治疗。在本研究开始时的非移植环境中，硼替佐米和伏立诺他已单独或联合研究一些 NHL 组织学，并显示出一些临床活性。在我们的中心，这种多发性骨髓瘤 (MM) 移植后联合疗法显示出可接受的毒性。因此，研究这种 ASCT 后 NHL 联合疗法似乎是合理的。方法 NHL 患者接受利妥昔单抗、卡莫司汀、依托泊苷、阿糖胞苷、美法仑 (R-BEAM)/卡莫司汀、依托泊苷、阿糖胞苷、美法仑 (BEAM) 的 ASCT 预处理。从急性移植相关毒性恢复后，开始静脉注射硼替佐米和口服伏立诺他 (BV) 联合治疗，总共 12 个周期（28 天）。结果 19 名患者在 ASCT 后接受了 BV 治疗。最常见的毒性是血液、胃肠道、代谢、疲劳和周围神经病变。中位随访时间为 10.3 年，其中 11 名患者 (58%) 存活且未出现疾病进展，12 名患者 (63%) 存活。结论 对于 NHL，BV 可以在 ASCT 后给予，并产生优异的无病生存率和总生存率。